Additionally, we present a case of a woman with pancreatic cancer harboring a VTCN1-NRG1 fusion whose tumor had progressed after multiple treatments but was responsive to pertuzumab and trastuzumab (anti-HER2 targeted antibodies). The gene discussed is NRG1; the disease is neoplasm.